DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for male breast carcinoma — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMale breast carcinoma maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedTamoxifenApproved drug
Structures already discussed alongside male breast carcinoma in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Crystal Structure of the Voltage-Gated Sodium Channel NavMs (F208L) — Tamoxifen has a real, experimentally solved structure in complex with this target (PDB 6SXF, 2.839 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet ctxdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6SXF · 2.839 Å · ligand Tamoxifen (CTX). Experimental structure, not a prediction.
What the evidence adds up to
Ten male patients with advanced metastatic male breast cancer were treated with cyproterone acetate, an anti-androgen with progestational properties, in a 1985 study. Seven of the ten achieved a response, with a median duration of eight months. Plasma testosterone and oestradiol levels fell significantly during therapy, but the size of that drop did not correlate with whether a patient responded. The authors described the drug as effective and well-tolerated in that small, uncontrolled series.
Male breast cancer accounts for less than 1% of all breast cancers and is associated with worse overall survival than female breast cancer, primarily because men present at a more advanced stage. A 2025 case report and review notes that patients often present late due to lack of awareness and poor socioeconomic status; the tumour is usually central and nipple involvement is common. The same review states that prognosis in men is very poor compared with women, and that postmastectomy chemotherapy, radiation, and adjuvant hormonal therapy are given to reduce recurrence and increase survival, but it also calls for urgent trials to determine the most effective treatment specifically for men.
Adjuvant tamoxifen is standard for early-stage male breast cancer, but a 2021 study reports a high rate of discontinuation. The reasons for stopping are not always clear, and the authors call for additional investigation into adherence. A 2021 review of management confirms that randomised controlled trials for male breast cancer are extremely limited, and that most practice is extrapolated from female breast cancer studies.
What is still missing are dedicated randomised controlled trials for male breast cancer, which are difficult to fund and recruit for given the rarity of the disease. Patient stratification by hormonal status, adherence monitoring in tamoxifen use, and prospective data on cyproterone acetate in larger, modern cohorts are also absent. The evidence base remains too thin to guide treatment with confidence beyond extrapolation from female breast cancer.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cancer · 1985 · 27 citations · open access
Cyproterone acetate in the treatment of metastatic cancer of the male breast
AbstractTen male patients with advanced cancer of the breast were treated with cyproterone acetate, an anti-androgenic compound with additional progestational properties. Seven patients achieved a response, for a median duration of 8 months. Plasma testosterone and estradiol levels fell significantly during therapy, but quantitatively this drop was not related to the therapeutic response. Cyproterone acetate is an effective and well-tolerated treatment for metastatic male breast cancer.
World Journal of Oncology · 2021 · 14 citations · open access
Management of Male Breast Cancer: The Journey so Far and Future Directions
AbstractMale breast cancer is now shown to be a unique entity and should be considered as a distinct disease. Given the relatively smaller number of cases, randomized controlled trials for treatment are extremely limited and majority of practices are derived from female breast cancer studies. This paper reviews available literature on surgical, radiation, and systemic therapies for male breast cancer, and discusses current practice recommendations.
Adjuvant tamoxifen adherence in male patients with breast cancer: An ongoing challenge
AbstractMale breast cancer, a rare disease, is usually treated with adjuvant tamoxifen during early stages. Unfortunately, studies suggest a high rate of discontinuing adjuvant tamoxifen, but reasons for stopping this treatment are not always clear, and additional studies investigating this are needed.
Trends in Urology & Men s Health · 2016 · 1 citations · open access
Diagnosis and management of breast cancer in men
AbstractMale breast cancer accounts for less than 1% of all breast cancer cases. Compared with female breast cancer, it is associated with a worse overall survival, predominantly due to advanced stage at presentation. 1 The authors discuss the evidence to date regarding the epidemiology, clinical presentation and mode of diagnosis, as well as current treatment strategies.
Asian Journal of Pharmaceutical Research and Health Care · 2025 · 0 citations · open access
Male Breast Cancer: Case Report with Review of Literature and Insights into Gender-specific Considerations
AbstractMale breast cancer is an extremely rare entity accounting for ˂1% of cancers in males and still remains an unaddressed issue. The patients usually present at an advanced stage due to the lack of awareness and poor socioeconomic status. The site of male breast cancer is usually the central region, and nipple involvement is more common. Although the management of male breast cancers is almost similar to female breast cancers, the prognosis is very poor in males when compared to females. Long-standing breast lesions in males should not be ignored else it leads to delay in the diagnosis. As surgery is very challenging in the male breast because of a paucity of breast lesion, there is an urgent need for trials for the most effective treatment in men with breast cancer. Postmastectomy chemotherapy and radiation therapy are usually given to decrease recurrence along with adjuvant hormonal therapy which has an effect on increasing survival rates.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
